Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.43 |
| ▸ | SRC | P12931 | 3/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 2/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24104689 | 0.86 | TTK (0.42) | SRCAURKBFLT3TTKAURKA | |
| SCHEMBL30167709 | 0.86 | TTK (0.42) | SRCAURKBFLT3TTKAURKA | |
| SCHEMBL24105038 | 0.86 | CYP11B1 (0.54) | CYP11B1SRCCYP19A1CYP17A1TTK | |
| SCHEMBL24104659 | 0.82 | CYP19A1 (0.40) | CYP11B1CYP19A1AURKBCYP11B2 | |
| SCHEMBL30167690 | 0.82 | CYP19A1 (0.40) | CYP11B1CYP19A1AURKBCYP11B2 | |
| SCHEMBL30168171 | 0.81 | EIF2AK4 (0.46) | SRCAURKBFLT3TTKAURKA | |
| Hydrochloric Acid SCHEMBL30168143 | 0.81 | EIF2AK4 (0.45) | SRCAURKBFLT3TTKAURKA | |
| SCHEMBL24104677 | 0.81 | SRC (0.44) | SRCAURKBFLT3TTKAURKA | |
| SCHEMBL24910461 | 0.79 | SRC (0.43) | SRCAURKBFLT3TTKAURKA | |
| SCHEMBL25173790 | 0.78 | TTK (0.48) | SRCTTKAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | XDH, MYD88, IKZF3 | CYP11B1 1126/4885SRC 2189/4885CYP19A1 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.